We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01068704
Recruitment Status : Completed
First Posted : February 15, 2010
Last Update Posted : October 12, 2015
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to determine if BMS-690514 + letrozole will be more effective than lapatinib + letrozole in patients who have metastatic hormone receptor positive breast cancer after developing progressive disease immediately following adjuvant antiendocrine therapy

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: BMS-690514 Drug: Lapatinib Drug: Letrozole Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy
Study Start Date : June 2010
Primary Completion Date : December 2010
Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: BMS-690514 + Letrozole Drug: BMS-690514
Tablets, Oral, 200 mg, once daily, ~ 12 months depending on response
Drug: Letrozole
Tablets, Oral, 2.5 mg, once daily, ~ 12 months depending on response
Active Comparator: Lapatinib + Letrozole Drug: Lapatinib
Tablets, Oral, 1500 mg, once daily, ~ 12 months depending on response
Drug: Letrozole
Tablets, Oral, 2.5 mg, once daily, ~ 12 months depending on response

Primary Outcome Measures :
  1. Clinical Benefit Rate defined as percentage of subjects with a complete response, partial response, or stable disease for at least 6 months [ Time Frame: Every 8 weeks according to CT scan ]

Secondary Outcome Measures :
  1. Progression Free Survival: defined as time to disease progression [ Time Frame: Every 8 weeks ]
  2. Objective Response Rate: defined as percentage of subjects with 'complete response' or 'partial response' [ Time Frame: Every 8 weeks ]
  3. Frequency and severity of adverse events in all subjects [ Time Frame: Every 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Documented invasive breast cancer
  • Greater than 10% tumor cells positive for estrogen receptor and/or progesterone receptor
  • HER2+ and HER2- (Human Epidermal growth factor Receptor) disease
  • Rapid disease progression despite treatment with tamoxifen, anastrozole or exemestane
  • ECOG Performance status = 0 or 1

Exclusion Criteria:

  • Prior hormonal therapy for metastatic disease
  • Prior hormonal therapy with letrozole for adjuvant disease
  • Symptomatic brain metastases
  • Prior treatment with any tyrosine kinase inhibitor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01068704

United States, Texas
Texas Oncology-Abilene
Abilene, Texas, United States, 79606
Texas Oncology-Beaumont
Beaumont, Texas, United States, 77702
Us Oncology Central Pharmacy
Fort Worth, Texas, United States, 76177
United States, Washington
Yakima Valley Memorial Hospital/North Star Lodge
Yakima, Washington, United States, 98902
Local Institution
Rosario, Santa Fe, Argentina, S2000DSK
Local Institution
La Rioja, Argentina, 5300
Local Institution
Colima, Mexico, 28030
Local Institution
Lima, Peru, 34
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

Additional Information:
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01068704     History of Changes
Other Study ID Numbers: CA187-016
2009-016622-13 ( EudraCT Number )
First Posted: February 15, 2010    Key Record Dates
Last Update Posted: October 12, 2015
Last Verified: September 2015

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Protein Kinase Inhibitors